The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid

Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program

John T. Grbic, Dennis M. Black, Kenneth W. Lyles, David M. Reid, Eric Orwoll, Michael McClung, Christina Bucci-Rechtweg, Guoqin Su

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial found one case of osteonecrosis of the jaw (ONJ) in a patient with postmenopausal osteoporosis (OP) treated with 5 milligrams of zoledronic acid (ZOL) once yearly and one case in a patient receiving a placebo. The authors examined ONJ incidence in four additional clinical trials involving patients with osteopenia or OP who were treated with ZOL, and they analyzed levels of the bone resorption marker serum β C-telopeptide (S-CTx) to assess its usefulness in predicting the risk of developing ONJ. Methods. To determine ONJ prevalence, an independent committee conducted a masked review of the clinical trials' adverse events databases for cases meeting predefined criteria for ONJ. The committee collected S-CTx level data for subsets of patients from these trials. Results. The results of the four additional clinical trials revealed no further cases of ONJ. The S-CTx levels commonly were lower than 0.15 nanograms per milliliter, with no correlation to the incidence of ONJ. Conclusions. In the clinically diverse group of 5,903 patients who received ZOL in five clinical trials, ONJ incidence was less than one in 14,200 patient = treatment-years. Data from four clinical trials indicated that S-CTx levels lower than 0.15 ng/mL were common among patients receiving ZOL for treatment of OP and were not associated with ONJ. Clinical Implications. Occurrences of ONJ have been rare in patients with OP who are receiving ZOL. Whereas low S-CTx values may be common in patients receiving bisphosphonates for OP therapy, they are not associated necessarily with an increased risk of developing ONJ.

Original languageEnglish (US)
Pages (from-to)1365-1370
Number of pages6
JournalJournal of the American Dental Association
Volume141
Issue number11
StatePublished - Nov 2010

Fingerprint

zoledronic acid
Osteonecrosis
Jaw
Clinical Trials
Incidence
Health
Osteoporosis

Keywords

  • Bisphosphonates
  • Osteonecrosis of the jaw
  • Serum C-telopeptide
  • Zoledronic acid

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid : Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. / Grbic, John T.; Black, Dennis M.; Lyles, Kenneth W.; Reid, David M.; Orwoll, Eric; McClung, Michael; Bucci-Rechtweg, Christina; Su, Guoqin.

In: Journal of the American Dental Association, Vol. 141, No. 11, 11.2010, p. 1365-1370.

Research output: Contribution to journalArticle

Grbic, John T. ; Black, Dennis M. ; Lyles, Kenneth W. ; Reid, David M. ; Orwoll, Eric ; McClung, Michael ; Bucci-Rechtweg, Christina ; Su, Guoqin. / The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid : Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. In: Journal of the American Dental Association. 2010 ; Vol. 141, No. 11. pp. 1365-1370.
@article{032baee5884641cab3cae6a99e6ec089,
title = "The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program",
abstract = "Background. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial found one case of osteonecrosis of the jaw (ONJ) in a patient with postmenopausal osteoporosis (OP) treated with 5 milligrams of zoledronic acid (ZOL) once yearly and one case in a patient receiving a placebo. The authors examined ONJ incidence in four additional clinical trials involving patients with osteopenia or OP who were treated with ZOL, and they analyzed levels of the bone resorption marker serum β C-telopeptide (S-CTx) to assess its usefulness in predicting the risk of developing ONJ. Methods. To determine ONJ prevalence, an independent committee conducted a masked review of the clinical trials' adverse events databases for cases meeting predefined criteria for ONJ. The committee collected S-CTx level data for subsets of patients from these trials. Results. The results of the four additional clinical trials revealed no further cases of ONJ. The S-CTx levels commonly were lower than 0.15 nanograms per milliliter, with no correlation to the incidence of ONJ. Conclusions. In the clinically diverse group of 5,903 patients who received ZOL in five clinical trials, ONJ incidence was less than one in 14,200 patient = treatment-years. Data from four clinical trials indicated that S-CTx levels lower than 0.15 ng/mL were common among patients receiving ZOL for treatment of OP and were not associated with ONJ. Clinical Implications. Occurrences of ONJ have been rare in patients with OP who are receiving ZOL. Whereas low S-CTx values may be common in patients receiving bisphosphonates for OP therapy, they are not associated necessarily with an increased risk of developing ONJ.",
keywords = "Bisphosphonates, Osteonecrosis of the jaw, Serum C-telopeptide, Zoledronic acid",
author = "Grbic, {John T.} and Black, {Dennis M.} and Lyles, {Kenneth W.} and Reid, {David M.} and Eric Orwoll and Michael McClung and Christina Bucci-Rechtweg and Guoqin Su",
year = "2010",
month = "11",
language = "English (US)",
volume = "141",
pages = "1365--1370",
journal = "Journal of the American Dental Association",
issn = "0002-8177",
publisher = "American Dental Association",
number = "11",

}

TY - JOUR

T1 - The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid

T2 - Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program

AU - Grbic, John T.

AU - Black, Dennis M.

AU - Lyles, Kenneth W.

AU - Reid, David M.

AU - Orwoll, Eric

AU - McClung, Michael

AU - Bucci-Rechtweg, Christina

AU - Su, Guoqin

PY - 2010/11

Y1 - 2010/11

N2 - Background. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial found one case of osteonecrosis of the jaw (ONJ) in a patient with postmenopausal osteoporosis (OP) treated with 5 milligrams of zoledronic acid (ZOL) once yearly and one case in a patient receiving a placebo. The authors examined ONJ incidence in four additional clinical trials involving patients with osteopenia or OP who were treated with ZOL, and they analyzed levels of the bone resorption marker serum β C-telopeptide (S-CTx) to assess its usefulness in predicting the risk of developing ONJ. Methods. To determine ONJ prevalence, an independent committee conducted a masked review of the clinical trials' adverse events databases for cases meeting predefined criteria for ONJ. The committee collected S-CTx level data for subsets of patients from these trials. Results. The results of the four additional clinical trials revealed no further cases of ONJ. The S-CTx levels commonly were lower than 0.15 nanograms per milliliter, with no correlation to the incidence of ONJ. Conclusions. In the clinically diverse group of 5,903 patients who received ZOL in five clinical trials, ONJ incidence was less than one in 14,200 patient = treatment-years. Data from four clinical trials indicated that S-CTx levels lower than 0.15 ng/mL were common among patients receiving ZOL for treatment of OP and were not associated with ONJ. Clinical Implications. Occurrences of ONJ have been rare in patients with OP who are receiving ZOL. Whereas low S-CTx values may be common in patients receiving bisphosphonates for OP therapy, they are not associated necessarily with an increased risk of developing ONJ.

AB - Background. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial found one case of osteonecrosis of the jaw (ONJ) in a patient with postmenopausal osteoporosis (OP) treated with 5 milligrams of zoledronic acid (ZOL) once yearly and one case in a patient receiving a placebo. The authors examined ONJ incidence in four additional clinical trials involving patients with osteopenia or OP who were treated with ZOL, and they analyzed levels of the bone resorption marker serum β C-telopeptide (S-CTx) to assess its usefulness in predicting the risk of developing ONJ. Methods. To determine ONJ prevalence, an independent committee conducted a masked review of the clinical trials' adverse events databases for cases meeting predefined criteria for ONJ. The committee collected S-CTx level data for subsets of patients from these trials. Results. The results of the four additional clinical trials revealed no further cases of ONJ. The S-CTx levels commonly were lower than 0.15 nanograms per milliliter, with no correlation to the incidence of ONJ. Conclusions. In the clinically diverse group of 5,903 patients who received ZOL in five clinical trials, ONJ incidence was less than one in 14,200 patient = treatment-years. Data from four clinical trials indicated that S-CTx levels lower than 0.15 ng/mL were common among patients receiving ZOL for treatment of OP and were not associated with ONJ. Clinical Implications. Occurrences of ONJ have been rare in patients with OP who are receiving ZOL. Whereas low S-CTx values may be common in patients receiving bisphosphonates for OP therapy, they are not associated necessarily with an increased risk of developing ONJ.

KW - Bisphosphonates

KW - Osteonecrosis of the jaw

KW - Serum C-telopeptide

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=78650428054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650428054&partnerID=8YFLogxK

M3 - Article

VL - 141

SP - 1365

EP - 1370

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

SN - 0002-8177

IS - 11

ER -